Jenex Advisory Board
Leonidas Notidis has spent nearly two decades advising Senior leadership teams from multinational corporations on entering global retail markets. As a previous Senior Director of Negotiation Strategy for a global leader in negotiation, he has consulted and coached C-suite leadership teams from over 200 of the Fortune 500 companies. His in-depth knowledge of the Retail and Pharmaceutical industry and the dynamics of the North American market have seen him take on the role of teacher, lecturer, consultant and practitioner. Having previously served on the Board of The Jenex Corporation, he is proud to lend his expertise from the pharmaceutical industry to once again build strategies to maximize the enormous potential present.
Joseph is involved in the early stage capital markets as an investor and sits on numerous Boards of Advisors in the healthcare & cannabis, technology and financial services industries. He is also the founding member of the Montreal chapter of the Private Capital Markets Association of Canada (PCMA) and is on the National Board of Directors for Canada. Over the past 35 years, Joseph has completed dozens of restructuring, due diligence and acquisition mandates in numerous industries on behalf of private equity and venture capital firms and industry clients. Joseph has directed over 200 conferences, seminars and workshops, has been a board member of several private and public organizations and is also an investor in a number of early stage public companies in Canada and the USA. Mr. Galli is the Chairman of PENTOR Finance, a residential mortgage lending company.
Stephen McNeill is a marketing strategist who has been helping businesses increase sales through innovative solutions. As managing partner of Q4 Communications, he has been instrumental in the evolution of Q4 from traditional marketing to digital advertising, sales funnels, chatbots and other emerging technologies that are having significant success in generating leads, and sales, for clients. He has been working in the cannabis industry for the past 5 years and is an associate of 3 West Management Group, an Ontario-based consulting firm of pharmaceutical, biomed and medical device experts with over 30 years experience in product launches, sales and marketing.
Michael is leveraging 20 years of senior commercial roles in the pharmaceutical/OTC industry to advise promising stakeholders in the medical device and cannabis industry. Michael's breadth of experience includes multiple therapy areas at both Global and Affiliate operations at 3 major organizations- GlaxoWellcome, Eli Lilly, and, most recently, Novartis Pharma. Senior roles have included New Product Planning, Market Research, Marketing, Sales, Brand Planning and extensive collaboration with Clinical, Health Policy & Regulation divisions. Michael has been an active team leader during all phases of product development from 6 years pre-launch through launch through to generic introduction. Michael has also served as a Global Expert Consultant on Customer Segmentation and Direct-To-Consumer marketing.